Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of February 2022. The report discloses significant changes in the company's senior management structure, specifically regarding the Chief Financial Officer (CFO) position.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Departure of CFO: Ms. Dorit Kreiner will conclude her position as Chief Financial Officer effective March 23, 2022. The departure is not attributed to any disagreement with the company regarding operations, policies, or practices.
- Appointment of Interim CFO: Mr. Alex Taskar, a former CFO of Evogene (serving from January 2017 to February 2019), has been appointed as Interim Chief Financial Officer.
Outlook, Risks, and Management Commentary
Management expressed gratitude to Ms. Kreiner for her service. Mr. Taskar brings extensive financial experience, having previously served as CFO for Valire Software, Orsus Solutions, and HP Israel. He holds a B.A. and M.A. in Economics from Tel-Aviv University. The filing notes that this report is incorporated by reference into specific registration statements (Form F-3 and Form S-8).
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (March 23, 2022).
- Verify the background and prior tenure of the new Interim CFO, Mr. Alex Taskar.
- Check subsequent filings for the appointment of a permanent CFO to replace the interim arrangement.
- Review the referenced registration statements (File Nos. 333-253300, 333-193788, 333-201443, 333-203856, and 333-259215) for updated disclosures.